NDA 021894 · Bausch
Xenazine
Tetrabenazine · Oral · Vesicular Monoamine Transporter 2 Inhibitor
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Sep 13, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2008
Aug 15, 2008
Approved uses
1
Original approval plus efficacy supplements
Registered trials
13
6 Phase 3, 0 recruiting
FAERS reports
7,327
4,082 serious, 1,533 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: DEPRESSION AND SUICIDALITY XENAZINE can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington’s disease. Anyone considering the use of XENAZINE must balance the risks of depression and suicidality with the clinical need for control of chorea. Close observation of patients for the emergence or worsening of depression, suicidality, or unusual changes in behavior should accompany therapy. Patients, their caregivers, and families should be informed of the risk of depression and suicidality and should be instructed to report behaviors of concern promptly to the treating physician. Particular caution should be exercised in treating patients with a history of depression or prior suicide attempts or ideation, which are increased in frequency in Huntington’s disease. XENAZINE is contraindicated in patients who are actively suicidal,...
What it is approved for
From the label in effect Nov 6, 2026.
XENAZINE is indicated for the treatment of chorea associated with Huntington’s disease. XENAZINE is a vesicular monoamine transporter 2 (VMAT) inhibitor indicated for the treatment of chorea associated with Huntington’s disease. ( 1 )
Mechanism: The precise mechanism by which XENAZINE (tetrabenazine) exerts its anti-chorea effects is unknown but is believed to be related to its effect as a reversible depletor of monoamines (such as dopamine, serotonin, norepinephrine, and histamine) from nerve terminals. Tetrabenazine reversibly inhibits the human vesicular monoamine transporter type 2 (VMAT2) (K i ≈ 100 nM), resulting in decreased uptake of monoamines into synaptic vesicles and depletion of monoamine stores. Human VMAT2 is also inhibited by dihydrotetrabenazine (HTBZ), a mixture of α-HTBZ and β-HTBZ. α- and β-HTBZ, major circulating...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 15, 2008 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLetterReviewSummary Review
2 products under this application
- XENAZINE · TETRABENAZINE 12.5MG · TABLET, ORAL · Prescription · TE AB
- XENAZINE · TETRABENAZINE 25MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Tetrabenazine" as an intervention, any sponsor and status, largest first.
- Neuroleptic and Huntington Disease Comparison of : Olanzapine, la Tetrabenazine and TiapridePivotal-lookingCompleted
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT00632645 · 180 participants · Start Apr 2009 · Primary completion Apr 28, 2017
Drug: Olanzapine; Xenazine and 1 more · For: Huntington Disease
Sites: Créteil, France
Sathbhavana Brain ClinicAcademic, hospital or other
NCT04523935 · 131 participants · Start Dec 7, 2005 · Primary completion Aug 4, 2020
Drug: Baclofen, Diazepam, Clonazepam, Trihexyphenidyl, Tetrabenazine, Gabapentin, Topiramate, Lamotrigine, Amitriptyline. · For: Cerebral Palsy; Excessive Crying; Pain
- Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington DiseasePivotal-lookingCompleted
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT04102579 · 128 participants · Start Nov 13, 2019 · Primary completion Oct 15, 2021
Drug: Valbenazine; Placebo · For: Chorea, Huntington
Sites: Birmingham, Alabama; Little Rock, Arkansas; La Jolla, California · 46 sites in all
- Alternatives for Reducing Chorea in Huntington DiseasePivotal-lookingCompleted
Auspex Pharmaceuticals, Inc.Industry
NCT01897896 · 119 participants · Start Nov 12, 2013 · Primary completion Aug 21, 2017
Drug: SD-809 · For: Chorea Associated With Huntington Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Fayetteville, Arkansas · 38 sites in all
- First Time Use of SD-809 in Huntington DiseasePivotal-lookingCompleted
Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
NCT01795859 · 90 participants · Start Aug 5, 2013 · Primary completion Dec 5, 2014
Drug: SD-809; Placebo · For: Chorea
Sites: Birmingham, Alabama; Phoenix, Arizona; Fayetteville, Arkansas · 43 sites in all
- Xenazine in Late Dyskinetic Syndrome With NeurolepticsPivotal-lookingCompleted
Centre Hospitalier Universitaire, AmiensAcademic, hospital or other
NCT01543321 · 54 participants · Start May 14, 2012 · Primary completion May 18, 2017
Drug: Tetrabenazine; Placebo · For: Tardive Dyskinesia
Sites: Amiens, France; Aix-en-Provence, France; Bordeaux, France · 19 sites in all
Dr. Reddy's Laboratories Limited, IndiaIndustry
NCT03702855 · 48 participants · Start Dec 2015 · Primary completion Dec 2015
Drug: Tetrabenazine Tablets 25 mg · For: Healthy
Sites: Navi Mumbai, India
Dr. Reddy's Laboratories Limited, IndiaIndustry
NCT03696329 · 48 participants · Start Oct 2015 · Primary completion Nov 2015
Drug: Tetrabenazine Tablets 25 mg · For: Healthy
Sites: Navi Mumbai, India
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death1,222
- off label use1,138
- drug ineffective708
- depression476
- somnolence451
- fatigue361
- fall318
- hospitalisation301
- insomnia276
- intentional product use issue274
- anxiety263
- drug administration error241
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 8 |
| 2005 | 4 |
| 2006 | 3 |
| 2007 | 6 |
| 2008 | 4 |
| 2009 | 187 |
| 2010 | 450 |
| 2011 | 279 |
| 2012 | 319 |
| 2013 | 353 |
| 2014 | 1,453 |
| 2015 | 1,833 |
| 2016 | 560 |
| 2017 | 699 |
| 2018 | 201 |
| 2019 | 139 |
| 2020 | 145 |
| 2021 | 162 |
| 2022 | 124 |
| 2023 | 97 |
| 2024 | 119 |
| 2025 | 91 |
| 2026 | 91 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Xenazine (Tetrabenazine)
2024 spending
$5.6M
Beneficiaries
23
151 claims
Per beneficiary
$245,537
$291.08 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $22,369,146 |
| 2021 | $14,981,265 |
| 2022 | $10,860,126 |
| 2023 | $9,064,543 |
| 2024 | $5,647,362 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Updating the recommendations for treatment of tardive syndromes: A systematic review of new evidence and practical treatment algorithm.
Bhidayasiri R, Jitkritsadakul O, Friedman JH, et al. · J Neurol Sci 2018 · Research Support, Non-U.S. Gov't, Systematic Review
- The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study.
Frank S, Testa C, Edmondson MC, et al. · CNS Drugs 2022 · Multicenter Study, Randomized Controlled Trial
- Managing Dystonia in Partington Syndrome.
Pichon E, Alioth A, Catalano Chiuvé S, et al. · Mov Disord Clin Pract 2026 · Case Reports, Systematic Review
- Tetrabenazine and movement disorders.
Asher SW, Aminoff MJ · Neurology 1981 · Clinical Trial, Research Support, Non-U.S. Gov't
- Real-World Experience With VMAT2 Inhibitors.
Niemann N, Jankovic J · Clin Neuropharmacol 2019 · Pragmatic Clinical Trial
- Tetrabenazine treatment in movement disorders.
Paleacu D, Giladi N, Moore O, et al. · Clin Neuropharmacol 2004 · Clinical Trial, Multicenter Study
Sponsor: Bausch
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.